Astrazeneca Dividends - AZN

Trade Now

Capital at risk

Stock Name	Stock Symbol	Market	Stock Type
Astrazeneca Plc	AZN	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	0.00	0.0%	9,944.00	01:00:00

Open Price	Low Price	High Price	Close Price	Previous Close
				9,944.00

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Astrazeneca AZN Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
29/07/2022	Interim	USX	93	31/12/2021	31/12/2022	11/08/2022	12/08/2022	12/09/2022	0
10/02/2022	Interim	USX	197	31/12/2020	31/12/2021	24/02/2022	25/02/2022	28/03/2022	287
29/07/2021	Interim	USX	90	31/12/2020	31/12/2021	12/08/2021	13/08/2021	13/09/2021	0
16/02/2021	Interim	USX	190	31/12/2019	31/12/2020	25/02/2021	26/02/2021	29/03/2021	280
30/07/2020	Interim	USX	90	31/12/2019	31/12/2020	13/08/2020	14/08/2020	14/09/2020	0
14/02/2020	Interim	USX	190	31/12/2018	31/12/2019	27/02/2020	28/02/2020	30/03/2020	280
25/07/2019	Interim	USX	90	31/12/2018	31/12/2019	08/08/2019	09/08/2019	09/09/2019	0
14/02/2019	Final	USX	190	31/12/2017	31/12/2018	28/02/2019	01/03/2019	27/03/2019	280
26/07/2018	Interim	USX	90	31/12/2017	31/12/2018	09/08/2018	10/08/2018	10/09/2018	0
02/02/2018	Final	USX	190	31/12/2016	31/12/2017	15/02/2018	16/02/2018	19/03/2018	280
27/07/2017	Interim	USX	90	31/12/2016	31/12/2017	10/08/2017	11/08/2017	11/09/2017	0
02/02/2017	Final	USX	190	31/12/2015	31/12/2016	16/02/2017	17/02/2017	20/03/2017	280
28/07/2016	Interim	USX	90	31/12/2015	31/12/2016	11/08/2016	12/08/2016	12/09/2016	0
04/02/2016	Final	USX	190	31/12/2014	31/12/2015	18/02/2016	19/02/2016	21/03/2016	280
30/07/2015	Interim	USX	90	31/12/2014	31/12/2015	13/08/2015	14/08/2015	14/09/2015	0
05/02/2015	Final	USX	190	31/12/2013	31/12/2014	19/02/2015	20/02/2015	23/03/2015	280
31/07/2014	Interim	USX	90	31/12/2013	31/12/2014	13/08/2014	15/08/2014	15/09/2014	0
06/02/2014	Final	USX	190	31/12/2012	31/12/2013	19/02/2014	21/02/2014	24/03/2014	280
01/08/2013	Interim	USX	90	31/12/2012	31/12/2013	14/08/2013	16/08/2013	16/09/2013	0
31/01/2013	Final	USX	190	31/12/2011	31/12/2012	13/02/2013	15/02/2013	18/03/2013	280
26/07/2012	Interim	USX	90	31/12/2011	31/12/2012	08/08/2012	10/08/2012	10/09/2012	0
02/02/2012	Final	USX	195	31/12/2010	31/12/2011	15/02/2012	17/02/2012	19/03/2012	280
28/07/2011	Interim	USX	85	31/12/2010	31/12/2011	03/08/2011	05/08/2011	12/09/2011	0
27/01/2011	Final	USX	185	31/12/2009	31/12/2010	02/02/2011	04/02/2011	14/03/2011	255
29/07/2010	Interim	USX	70	31/12/2009	31/12/2010	02/08/2010	04/08/2010	13/09/2010	0
28/01/2010	Final	USX	171	31/12/2008	31/12/2009	03/02/2010	05/02/2010	15/03/2010	230
30/07/2009	Interim	USX	59	30/12/2008	30/06/2009	05/08/2009	07/08/2009	14/09/2009	0
29/01/2009	Final	USX	150	31/12/2007	31/12/2008	04/02/2009	06/02/2009	16/03/2009	205
31/07/2008	Interim	USX	55	30/12/2007	30/06/2008	08/08/2008	06/08/2008	15/09/2008	0
31/01/2008	Final	USX	135	31/12/2006	31/12/2007	06/02/2008	08/02/2008	17/03/2008	187
26/07/2007	Interim	USX	52	30/06/2006	30/06/2007	08/08/2007	10/08/2007	17/09/2007	0
01/02/2007	Final	USX	123	31/12/2005	31/12/2006	07/02/2007	09/02/2007	19/03/2007	172
27/07/2006	Interim	USX	49	30/12/2005	30/06/2006	09/08/2006	11/08/2006	18/09/2006	0
01/02/2006	Final	USX	92	31/12/2004	31/12/2005	08/02/2006	10/02/2006	20/03/2006	130
29/07/2005	Interim	USX	38	30/12/2004	30/06/2005	10/08/2005	12/08/2005	19/09/2005	0
27/01/2005	Final	USX	64.5	31/12/2003	31/12/2004	09/02/2005	11/02/2005	21/03/2005	94
22/07/2004	Interim	USX	29.5	30/12/2003	30/06/2004	11/08/2004	13/08/2004	20/09/2004	0
29/01/2004	Final	USX	54	31/12/2002	31/12/2003	18/02/2004	20/02/2004	06/04/2004	79.5
24/07/2003	Interim	USX	25.5	30/12/2002	30/06/2003	20/08/2003	22/08/2003	06/10/2003	0
30/01/2003	Final	USX	47	31/12/2001	31/12/2002	19/02/2003	21/02/2003	07/04/2003	70
25/07/2002	Interim	USX	23	30/12/2001	30/06/2002	21/08/2002	23/08/2002	07/10/2002	0
31/01/2002	Final	USX	47	31/12/2000	31/12/2001	20/02/2002	22/02/2002	08/04/2002	70
26/07/2001	Interim	USX	23	30/12/2000	30/06/2001	22/08/2001	24/08/2001	05/10/2001	0
08/02/2001	Final	USX	47	31/12/1999	31/12/2000	21/02/2001	23/02/2001	09/04/2001	70
01/08/2000	Interim	USX	23	30/12/1999	30/06/2000	04/09/2000	08/09/2000	23/10/2000	0
24/02/2000	Final	USX	47	31/12/1998	31/12/1999	06/03/2000	10/03/2000	17/04/2000	70
03/08/1999	Interim	USX	23	30/12/1998	30/06/1999	06/09/1999	10/09/1999	25/10/1999	0

Top Dividend Posts

Top Posts
Posted at 04/10/2022 07:10 by lostabillion AZN eyeing up Avacta!?! Read Full Thread Follow Reply
Posted at 02/10/2022 11:03 by bostonborn Today's Questor in the telegraph has AZN as a buy. Can someone please post the complete article. It was tipped in the Times on Thursday or Friday. It may be a 'repeat' of this article. Summary of which was 'great pipeline of new drugs coming through over the next year or two, which should bring growth; also a 'safe' share' Read Full Thread Follow Reply
Posted at 26/9/2022 21:46 by sb34 AZN Plc share going to match £115 price anytime soon over the next few weeks ?? Read Full Thread Follow Reply
Posted at 12/9/2022 07:57 by gateside Dividend paid into my account this morning. Interactive Investor are always very prompt with their dividend payments. Read Full Thread Follow Reply
Posted at 29/7/2022 14:38 by philanderer ShoreCap stays at 'buy' on AstraZeneca, sees further upgrades ahead on product pipeline Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive". "AZN have delivered a strong second quarter, with Q2 benefitting from a full quarter of Alexion integration and several products beating consensus expectations," analyst Dr.Susie Jana said in a research note sent to clients. "Oncology was in line overall due to strong commercial execution and lower COVID-19 related headwinds than anticipated." The analyst also called attention to the fact that AstraZeneca was reinvesting its strong revenues into research and development. And there was more yet to come. "AZN has a strong mid to late-stage pipeline, we expect product and candidate related news flow in 2023 to lead to further upgrades. A strong set of results underpinning the long-term growth story," she added. "AZN shares trade on a FY23F PER of 16.8x, a c 5% premium versus US and European peers (mean 16.1x), which we believe is warranted based on its industry-leading earnings growth and pipeline prospects." Sharecast.com Read Full Thread Follow Reply
Posted at 29/7/2022 08:15 by gibbs1 AstraZeneca PLC on Friday reported a swing to second-quarter net loss after booking a large foreign-exchange charge in its accounts, but raised its full-year revenue guidance due to better-than-expected Covid-19 medicine revenue. The Anglo-Swedish pharma giant said it now expects to report a low twenties percentage rise in total revenue for the year, up from previous guidance of high teens percentage. It also said revenue from Covid-19 medicines are expected to be flat compared with 2021. It had previously guided for a low-to-mid twenties percentage fall. AstraZeneca posted a net loss of $372 million for the quarter compared with a profit of $1.19 billion for the same period a year earlier. Revenue for the quarter rose to $10.77 billion, from $8.22 billion. Revenue consensus was $10.45 billion. Core earnings per share--one of the company's preferred metrics--rose to $1.72 in the quarter, compared with $0.90 and a consensus of $1.57. Consensus figures have been taken from FactSet and are based on 16 analysts' projections. AstraZeneca reiterated that it expects core EPS growth in the mid-to-high twenties percentage. The board has increased its interim dividend to $0.93 a share compared with $0.90 for the first half of 2021. Write to Ian Walker at ian.walker@wsj.com (END) Dow Jones Newswires July 29, 2022 02:54 ET (06:54 GMT) Read Full Thread Follow Reply
Posted at 15/7/2022 11:35 by dudishes Waldron, yes sold GSK, got the gitters. AZN, two reasons, the buy in France and I think it's peaked for now. I'll be back (maybe catch the divi)! Read Full Thread Follow Reply
Posted at 08/7/2022 17:23 by waldron thought you were keeping AZN Dud and sold GSK Read Full Thread Follow Reply
Posted at 06/7/2022 15:31 by diku AZN paper is so rich... Read Full Thread Follow Reply
Posted at 14/2/2022 10:34 by beckers2008 HL View/Comment published on the 10th Feb: AstraZeneca's coronavirus vaccine has made it a household name worldwide, but the group's promise to sell the vaccine at cost ''during the pandemic'' means it's padded revenue but not profits. 2022 will pave a new road for the group's coronavirus medicines business--with vaccine sales waning and a monoclonal antibody treatment making up a larger proportion of sales, we can expect to see some of those dollars start to funnel through to the bottom line. This in addition to the potential growth runway coming from the Alexion acquisition have given management the confidence to increase shareholder returns, but remember dividends are variable and not guaranteed. Alexion brings rare disease treatments into the AZN fold, a fundamentally attractive area of the pharmaceutical market. The combination of Astra's massive distribution network and Alexion's specialized drugs should bring about a powerful windfall in the coming years. Rare diseases are, by definition, uncommon. In the past spending millions, perhaps billions, on researching a drug to treat a few tens of thousands of patients worldwide didn't make financial sense. Instead attention focused on treatments for common diseases, like asthma, with patients stretching into the tens of millions. As a result, only around 5% of designated rare diseases have approved treatments. More recently that attitude has shifted. While major diseases may have large markets, they also attract lots of competition. That means individual drugs companies can end up with a relatively small slice of a large pie. Competition in rare diseases is far lower - a drug company which develops a treatment for a previously unaddressed illness will likely end up serving the entire market and can probably attach a hefty price tag to boot. It's also unlikely a competitor will develop a more effective alternative, since competition is so much lower. Increased interest in the sector means the global rare disease market is forecasted to grow by a low double-digit percentage. Breaking into this market didn't come cheap, though. The acquisition more than doubled Astra's debt pile and sent free cash into the red. But this pales in comparison to the potential growth the combination offers. This is particularly true when it comes to emerging markets. Alexion's been primarily selling to the US and Europe, but under Astra's wing a greater proportion can be sold further afield. This is of course dependent on regulatory approval, but as AZN already has footholds in these markets it should make the process more efficient. Cash flow will be of utmost importance moving forward--debt now stands at more than 3 times underlying cash profits. With interest rates on the rise, we'd like to see that come down to more manageable levels. Shareholder returns are also marching higher, so the demands on cash are not insignificant. Any missteps in the Alexion integration, and the group will either have to saddle itself with more debt or trim the dividend. Overall we think Astra is pretty well placed. It's too early to say whether the Alexion deal will deliver on its potential, but a strong core business and the promise of rising coronavirus treatment profits are encouraging. If all goes to plan the future is bright. Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

AZN

Astrazenec..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20221006 07:05:38